Skip to main content
logo
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.180
+0.040 (3.51%)
At close: Jan 22, 2026, 4:00 PM EST
1.150
-0.030 (-2.54%)
After-hours: Jan 22, 2026, 5:40 PM EST

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $2.51M in the quarter ending September 30, 2025, with 139.37% growth. This brings the company's revenue in the last twelve months to $8.42M, down -10.03% year-over-year. In the year 2024, TScan Therapeutics had annual revenue of $2.82M, down -86.62%.

Revenue (ttm)
$8.42M
Revenue Growth
-10.03%
P/S Ratio
7.68
Revenue / Employee
$43,195
Employees
195
Market Cap
66.96M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20242.82M-18.23M-86.62%
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Metagenomi Therapeutics30.91M
ImmuCell27.77M
CervoMed6.16M
Equillium4.39M
BeyondSpring1.88M
aTyr Pharma190.00K
InflaRx73.73K
Adlai Nortye-1.35M
Revenue Rankings

TCRX News

More News